High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
accepted:
26
06
2021
pubmed:
30
6
2021
medline:
4
3
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis is associated with a high mortality rate. To investigate the drivers of EPC progression. We carried out genomic and transcriptomic profiling of metastatic EPC (mEPC), validation of the observed alterations in an EPC patient-derived cell line, confirmation of relevant observations in a large patient cohort of 30 tumour tissues, and successful treatment of a patient with mEPC under the identified treatment regimens. mEPC was characterized by a high tumour mutational burden (TMB) with an ultraviolet signature, widespread copy number alterations and gene expression changes that affected cancer-relevant cellular processes such as cell cycle regulation and proliferation, including a pathogenic TP53 (tumour protein 53) mutation, a copy number deletion in the CDKN2A (cyclin dependent kinase inhibitor 2A) region and a CTNND1/PAK1 [catenin delta 1/p21 (RAC1) activated kinase 1] gene fusion. The overexpression of EGFR (epidermal growth factor receptor), PAK1 and MAP2K1 (mitogen-activated protein kinase kinase 1; also known as MEK1) genes translated into strong protein expression and respective pathway activation in the tumour tissue. Furthermore, a patient-derived cell line was sensitive to EGFR and MEK inhibition, confirming the functional relevance of the pathway activation. Immunohistochemistry analyses in a large patient cohort showed the relevance of the observed changes to the pathogenesis of EPC. Our results indicate that mEPC should respond to immune or kinase inhibitor therapy. Indeed, the advanced disease of our index patient was controlled by EGFR-directed therapy and immune checkpoint inhibition for more than 2 years. Molecular profiling demonstrated high TMB and EGFR/MAPK pathway activation to be novel therapeutic targets in mEPC.
Sections du résumé
BACKGROUND
Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis is associated with a high mortality rate.
OBJECTIVES
To investigate the drivers of EPC progression.
METHODS
We carried out genomic and transcriptomic profiling of metastatic EPC (mEPC), validation of the observed alterations in an EPC patient-derived cell line, confirmation of relevant observations in a large patient cohort of 30 tumour tissues, and successful treatment of a patient with mEPC under the identified treatment regimens.
RESULTS
mEPC was characterized by a high tumour mutational burden (TMB) with an ultraviolet signature, widespread copy number alterations and gene expression changes that affected cancer-relevant cellular processes such as cell cycle regulation and proliferation, including a pathogenic TP53 (tumour protein 53) mutation, a copy number deletion in the CDKN2A (cyclin dependent kinase inhibitor 2A) region and a CTNND1/PAK1 [catenin delta 1/p21 (RAC1) activated kinase 1] gene fusion. The overexpression of EGFR (epidermal growth factor receptor), PAK1 and MAP2K1 (mitogen-activated protein kinase kinase 1; also known as MEK1) genes translated into strong protein expression and respective pathway activation in the tumour tissue. Furthermore, a patient-derived cell line was sensitive to EGFR and MEK inhibition, confirming the functional relevance of the pathway activation. Immunohistochemistry analyses in a large patient cohort showed the relevance of the observed changes to the pathogenesis of EPC. Our results indicate that mEPC should respond to immune or kinase inhibitor therapy. Indeed, the advanced disease of our index patient was controlled by EGFR-directed therapy and immune checkpoint inhibition for more than 2 years.
CONCLUSIONS
Molecular profiling demonstrated high TMB and EGFR/MAPK pathway activation to be novel therapeutic targets in mEPC.
Substances chimiques
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186-1199Informations de copyright
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Mishima Y, Morioka S. Oncogenic differentiation of the intraepidermal eccrine sweat duct: eccrine poroma, poroepithelioma and porocarcinoma. Dermatologica 1969; 138:238-50.
Nazemi A, Higgins S, Swift R et al. Eccrine porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg 2018; 44:1247-61.
Goto K, Takai T, Fukumoto T et al. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma. J Cutan Pathol 2016; 43:219-26.
Brown CW Jr, Dy LC. Eccrine porocarcinoma. Dermatol Ther 2008; 21:433-8.
Bosic M, Kirchner M, Brasanac D et al. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology 2018; 50:327-32.
Salih AM, Kakamad FH, Essa RA et al. Porocarcinoma: a systematic review of literature with a single case report. Int J Surg Case Rep 2017; 30:13-16.
Snow SN, Reizner GT. Eccrine porocarcinoma of the face. J Am Acad Dermatol 1992; 27:306-11.
Arslan D, Tatlı AM, Uysai M, Kaplan MA. Eccrine porocarcinoma: a case report and literature review. J Clin Exp Invest 2013; 4:370-3.
Mandaliya H, Nordman I. Metastatic eccrine porocarcinoma: a rare case of successful treatment. Case Rep Oncol 2016; 9:454-6.
Godillot C, Boulinguez S, Riffaud L et al. Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. Eur J Cancer 2018; 90:142-5.
Müller I, Strozyk E, Schindler S et al. Cancer cells employ nuclear caspase-8 to overcome the p53-dependent G2/M checkpoint through cleavage of USP28. Mol Cell 2020; 77:970-84.e7.
Niessner H, Schmitz J, Tabatabai G et al. PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res 2016; 22:5818-28.
Denisova E, Westphal D, Surowy HM et al. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies. Cancer Gene Ther 2021; https://doi.org/10.1038/s41417-021-00347-z.
Held L, Metzler G, Eigentler TK et al. Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome. J Cutan Pathol 2012; 39:1088-93.
Chudasama P, Mughal SS, Sanders MA et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 2018; 9:144.
Van der Auwera GA, Carneiro MO, Hartl C et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics 2013; 43:11.0.1-11.01.33.
Poplin R, Ruano-Rubio V, DePristo MA et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv 2018: https://doi.org/10.1101/201178 (preprint).
Lai Z, Markovets A, Ahdesmaki M et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 2016; 44:e108.
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38:e164.
Alexandrov LB, Kim J, Haradhvala NJ et al. The repertoire of mutational signatures in human cancer. Nature 2020; 578:94-101.
Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLOS Comput Biol 2016; 12:e1004873.
Oesper L, Satas G, Raphael BJ. Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics 2014; 30:3532-40.
Dobin A, Davis CA, Schlesinger F et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2012; 29:15-21.
Haas BJ, Dobin A, Li B et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol 2019; 20:213.
Gamazon ER, Segrè AV, van de Bunt M et al. Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat Genet 2018; 50:956-67.
Horak P, Klink B, Heining C et al. Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 2017; 141:877-86.
Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009; 28:51-63.
Schackmann RCJ, Tenhagen M, van de Ven RAH, Derksen PWB. p120-catenin in cancer - mechanisms, models and opportunities for intervention. J Cell Sci 2013; 126:3515-25.
Harms PW, Hovelson DH, Cani AK et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol 2016; 51:25-31.
Goh LK, Sorkin A. Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol 2013; 5:a017459.
Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-18.
Thibodeau ML, Bonakdar M, Zhao E et al. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. NPJ Precis Oncol 2018; 2:8.
Inman GJ, Wang J, Nagano A et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun 2018; 9:3667.
Dias-Santagata D, Lam Q, Bergethon K et al. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Mod Pathol 2011; 24:974-82.
Le LP, Dias-Santagata D, Pawlak AC et al. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One 2012; 7:e47290.
Zhang M, Biswas S, Qin X et al. Does Notch play a tumor suppressor role across diverse squamous cell carcinomas? Cancer Med 2016; 5:2048-60.
Corchado-Cobos R, García-Sancha N, González-Sarmiento R et al. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci 2020; 21:2956.
Gerber PA, Buhren BA, Schrumpf H et al. Mechanisms of skin aging induced by EGFR inhibitors. Support Care Cancer 2016; 24:4241-8.
Dummer R, Becker JC, Boser B et al. Successful therapy of metastatic eccrine poroma using perilesional interferon alfa and interleukin 2. Arch Dermatol 1992; 128:1127-8.
Lee KA, Cioni M, Robson A, Bataille V. Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab. BMJ Case Rep 2019; 12:e228917.
Hsu F-M, Zhang S, Chen BPC. Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Transl Cancer Res 2012; 1:22-34.
Tanaka N, Zhao M, Tang L et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene 2018; 37:1279-92.
Kashiwagi M, Ohba M, Chida K, Kuroki T. Protein kinase C eta (PKCη): its involvement in keratinocyte differentiation. J Biochem 2002; 132:853-7.
Newton AC. Protein kinase C as a tumor suppressor. Semin Cancer Biol 2018; 48:18-26.
Garg R, Benedetti LG, Abera MB et al. Protein kinase C and cancer: what we know and what we do not. Oncogene 2014; 33:5225-37.
Carbone M, Yang H, Pass HI et al. BAP1 and cancer. Nat Rev Cancer 2013; 13:153-9.
Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005; 24:2909-15.
de Celis JF, Bray SJ. The Abruptex domain of Notch regulates negative interactions between Notch, its ligands and Fringe. Development 2000; 127:1291-302.
Pelullo M, Zema S, Nardozza F et al. Wnt, Notch, and TGF-β pathways impinge on Hedgehog signaling complexity: an open window on cancer. Front Genet 2019; 10:711.
Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst 2017; 109:djw332.
Yamulla RJ, Kane EG, Moody AE et al. Testing models of the APC tumor suppressor/β-catenin interaction reshapes our view of the destruction complex in Wnt signaling. Genetics 2014; 197:1285-302.
Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol 2005; 58:225-36.
Zhu G-F, Xu Y-W, Li J et al. Mir20a/106a-WTX axis regulates RhoGDIa/CDC42 signaling and colon cancer progression. Nat Commun 2019; 10:112.
Boutet A, Comai G, Schedl A. The WTX/AMER1 gene family: evolution, signature and function. BMC Evol Biol 2010; 10:280.
Ebert MPA, Yu J, Hoffmann J et al. Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 2003; 21:1708-14.
Rodríguez-Escudero I, Oliver MD, Andrés-Pons A et al. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum Mol Genet 2011; 20:4132-42.
Burke JE. Structural basis for regulation of phosphoinositide kinases and their involvement in human disease. Mol Cell 2018; 71:653-73.
Thomas R, Weihua Z. Rethink of EGFR in cancer with its kinase independent function on board. Front Oncol 2019; 9:800.
Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010; 3:8.